Aoki, Tomokazu http://orcid.org/0000-0003-0405-7680
Kagawa, Naoki
Sugiyama, Kazuhiko
Wakabayashi, Toshihiko
Arakawa, Yoshiki
Yamaguchi, Shigeru
Tanaka, Shota
Ishikawa, Eiichi
Muragaki, Yoshihiro
Nagane, Motoo
Nakada, Mitsutoshi
Suehiro, Satoshi
Hata, Nobuhiro
Kuroda, Junichiro
Narita, Yoshitaka
Sonoda, Yukihiko
Iwadate, Yasuo
Natsumeda, Manabu
Nakazato, Yoichi
Minami, Hironobu
Hirata, Yuki
Hagihara, Shunsuke
Nishikawa, Ryo
Funding for this research was provided by:
Ono Pharmaceutical
Bristol-Myers Squibb
Article History
Received: 30 March 2021
Accepted: 7 September 2021
First Online: 29 September 2021
Declarations
:
: T. Aoki, N. Kagawa, T. Wakabayashi, S. Yamaguchi, E. Ishikawa, S. Suehiro, J. Kuroda, Y. Iwadate, M. Natsumeda, Y. Nakazato, and S. Hagihara have no conflicts of interest to declare. K. Sugiyama has received research funding from Ono Pharmaceutical Co., Ltd., Daiichi-Sankyo Co., Ltd., and Sumitomo Dainippon Pharma Co. Ltd. Y. Arakawa has received research funding from Ono Pharmaceutical Co., Ltd., Siemens, Philips, Chugai Pharmaceutical Co., Ltd., Daiichi-Sankyo Co., Ltd., and Taiho Pharmaceutical Co., Ltd.; and honoraria from Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., and Daiichi-Sankyo Co., Ltd. S. Tanaka has received research funding from Eisai Co., Ltd., Ono Pharmaceutical Co., Ltd., and Sumitomo Dainippon Pharma Co. Ltd. Y. Muragaki has received lecture fees, honoraria, or other fees from Eisai Co., Ltd. and Novocure Limited. M. Nagane has received lecture fees, honoraria, or other fees from MSD and Ono Pharmaceutical Co., Ltd.; has received research funding from Toray Industries, Inc., AbbVie Inc., and Ono Pharmaceutical Co., Ltd.; and has received scholarship (incentive) endowments or research grants from Eisai Co., Ltd., Pfizer, Nippon Kayaku Co., Ltd., and Chugai Pharmaceutical Co., Ltd. M. Nakada has received research funding from Ono Pharmaceutical Co., Ltd.; and has received scholarship (incentive) endowments or research grants from Otsuka Pharmaceutical Co., Ltd., Stryker Corporation, Eisai Co., Ltd., MSD, and Chugai Pharmaceutical Co., Ltd. N. Hata has received research funding from Daiichi-Sankyo Co., Ltd. Y. Narita has received research funding from Eisai Co., Ltd., Ono Pharmaceutical Co., Ltd., AbbVie Inc., Bayer AG, Sumitomo Dainippon Pharma Co. Ltd., Taiho Pharmaceutical Co., Ltd., and Daiichi-Sankyo Co., Ltd. Y. Sonoda has received scholarship (incentive) endowments or research grants from Eisai Co., Ltd., Otsuka Pharmaceutical Co., Ltd., and Fujifilm. H. Minami has received lecture fees, honoraria, or other fees from Daiichi-Sankyo Co., Ltd. and Ono Pharmaceutical Co., Ltd.; has received research funding from Amgen Astellas BioPharma K.K., Bayer AG, Bristol-Myers Squibb, Daiichi-Sankyo Co., Ltd., Novartis, Pfizer, and Ono Pharmaceutical Co., Ltd.; and has received scholarship (incentive) endowments or research grants from Astellas, Bayer AG, Bristol-Myers Squibb, Chugai Pharmaceutical Co., Ltd., Daiichi-Sankyo Co., Ltd., Kyowa Kirin, Eli Lilly, Ono Pharmaceutical Co., Ltd., Pfizer, Taiho Pharmaceutical Co., Ltd., and Takeda Pharmaceutical Company Limited. Y. Hirata is an employee and shareholder at Ono Pharmaceutical Co., Ltd. R. Nishikawa has received manuscript fees from Eisai Co., Ltd.; has received research funding from AbbVie Inc., Daiichi-Sankyo Co., Ltd., Ono Pharmaceutical Co., Ltd., Toray Industries, Inc., and Medi-Physics, Inc.; and has received scholarship (incentive) endowments or research grants from Chugai Pharmaceutical Co., Ltd. and MSD.